Format

Send to

Choose Destination
Med Monatsschr Pharm. 2006 Jul;29(7):249-54; quiz 255-6.

[Bevacizumab. Progress in cancer therapy by antiangiogenesis].

[Article in German]

Author information

1
Apotheke des Klinikums der Johannes Gutenberg-Universität Mainz, Langenbeckstrasse 1, 55131 Mainz.

Abstract

Bevacizumab represents the first humanized monoclonal antibody with antiangiogenic properties which has been introduced in clinical oncology. The VEGF antagonist is used for the treatment of advanced colorectal cancer based on significant survivial benefits. Besides hypertension, proteinuria, wound healing disorders, bleeding and thromboembolic events appear to be related to bevacizumab. Optimization of combination therapy, new potential indications as well as pharmacoeconomic considerations represent the topics of current discussion regarding the novel monoclonal antibody.

PMID:
16866078
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center